How Will the Transthyretin Amyloidosis Treatment Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the transthyretin amyloidosis treatment market?
The transthyretin amyloidosis treatment market has grown significantly and is expected to expand from $5.52 billion in 2024 to $5.95 billion in 2025 at a CAGR of 7.8%. Growth in past years was influenced by rising disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy, and collaborative research efforts.
What will be the transthyretin amyloidosis treatment market size in the future?
The transthyretin amyloidosis treatment market is projected to experience strong growth, reaching $8.04 billion by 2029, with a CAGR of 7.8%. Growth will be fueled by an expanding therapeutic pipeline, increased genetic screening, global rare disease awareness, personalized medicine approaches, and improved treatment access. Trends include the emergence of combination therapies, strategic drug development partnerships, targeted approaches for peripheral and cardiac manifestations, patient education programs, and real-world evidence integration in treatment guidelines.
Get your transthyretin amyloidosis treatment market report here!
What main drivers are fueling expansion in the transthyretin amyloidosis treatment market?
The augmentation in funds devoted to research and development is anticipated to drive the expansion of the transthyretin amyloidosis treatment market. Such investments encompass financial accommodations for pursuits that serve to enhance scientific comprehension, conceive contemporary technologies, produce groundbreaking products, and enhance existing processes. A boost in funding for research and development facilitates the find and formulation of ground-breaking treatment alternatives for transthyretin amyloidosis. This includes innovative drugs, gene therapies, and precision medicine techniques, providing patients with more successful, focused treatment selections. For instance, Alnylam Pharmaceuticals, a US-based biopharmaceutical firm involved in the development of Vutrisiran, a therapy for ATTR amyloidosis, amplified its research and development investment from $792,156 in 2021 to $883,015 in 2022, signifying a growth of 11.49%. Consequently, the escalation in investment in research and development is set to fuel the transthyretin amyloidosis treatment market’s growth. The demographics of the aging population and its subsequent rise are forecasted to stimulate the transthyretin amyloidosis treatment market’s growth. Aging population alludes to a demographic change marked by a surge in the median age of a population due to lower fertility rates and increasing life expectancy. Aging significantly contributes to the risk factor for transthyretin amyloidosis (ATTR), and as the population ages, there is a higher prevalence of Transthyretin Amyloidosis cases. This results in an escalating pool of patients necessitating treatment. For instance, the World Health Organization, a Switzerland-based branch of the United Nations handling global public health, stated in October 2022 that every nation globally is witnessing a growth in both the quantity and proportion of older persons in the population. It is projected that by 2030, one in six individuals globally will be 60 years or older. Thus, the growth in the aging population’s demographics is propelling the transthyretin amyloidosis treatment market’s expansion.
What key areas define the segmentation of the global transthyretin amyloidosis treatment market?
The transthyretin amyloidosis treatment market covered in this report is segmented –
1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp
Who are the dominant players expanding their reach in the transthyretin amyloidosis treatment market?
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A
How are evolving market trends shaping transthyretin amyloidosis treatment Strategies?
Leading players in the transthyretin amyloidosis treatment marketplace are concentrating their efforts on the creation of novel and unique treatment modalities, such as specialized orphan drugs, to improve patient well-being and broaden available treatment alternatives. Eplontersen is an orphan drug that has been tailored to address the transthyretin amyloidosis condition and often enjoys regulatory incentives to aid its development. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a biotechnology research firm based in Canada, obtained approval from the Food and Drug Administration (FDA) for a new drug application for Eplontersen. This experimental orphan drug is designed for the treatment of familial transthyretin-mediated amyloid, leading to the advancement of polyneuropathy. Eplontersen is a medicinal compound created to reduce the production of transthyretin (TTR) protein, tackling both hereditary and sporadic types of ATTR amyloidosis (amyloid transthyretin amyloidosis). Eplontersen was bestowed with the orphan drug status by the FDA in 2022.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13129
Which regions are emerging as leaders in the transthyretin amyloidosis treatment market?
North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Neurotrophic Keratitis Treatment Global Market Report 2024
Pediatric Bladder Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report
Aspergillosis Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
